Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
intravenous injection
|
| gptkbp:approves |
gptkb:2010
gptkb:FDA |
| gptkbp:atccode |
L01 XX32
|
| gptkbp:casnumber |
680047-69-0
|
| gptkbp:chemical_formula |
C17 H22 Br N3 O4 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:defines |
gptkb:eribulin
E7389 eribulin mesylate injection |
| gptkbp:developed_by |
gptkb:Eisai_Co.,_Ltd.
|
| gptkbp:financials |
DB08883
|
| https://www.w3.org/2000/01/rdf-schema#label |
eribulin mesylate
|
| gptkbp:indication |
gptkb:Oncology
metastatic breast cancer |
| gptkbp:mechanism_of_action |
inhibits microtubule dynamics
|
| gptkbp:route_of_administration |
IV
|
| gptkbp:side_effect |
fatigue
nausea constipation peripheral neuropathy neutropenia |
| gptkbp:trade |
gptkb:Halaven
|
| gptkbp:used_for |
treatment of breast cancer
|
| gptkbp:weight |
421.35 g/mol
|
| gptkbp:bfsParent |
gptkb:Halaven
|
| gptkbp:bfsLayer |
6
|